EUVIMEDEUVIMED entdecken
Crossref

Clinical determinants of outcome following pelvic exenteration for locally advanced or locally recurrent rectal cancer

Laura E Gould, E Toby Pring, Alison Wallace, Nicola Hodges, Elaine M Burns, Colin W Steele, Campbell Sd Roxburgh, John T Jenkins

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.110347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Laura E Gould und 7 weiteren Autor:innen. Beteiligte Einrichtung: Complex Cancer Clinic, St Mark's- The National Bowel Hospital, Harrow, UK; School of Cancer Sciences, College of Medical, Veterinary & Life Sciences,…. Hauptthemen laut MEDLINE: Pelvic Exenteration, Rectal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: To assess the impact of clinical factors on survival in patients undergoing pelvic exenteration (PE) with curative intent for locally advanced rectal cancer (LARC) or locally recurrent rectal cancer (LRRC). METHODS: Retrospective analysis of consecutive patients undergoing PE between January 2008 and July 2021 at a tertiary referral centre. Baseline characteristics, comorbidities and neoadjuvant therapy were recorded. Influence of comorbidity was assessed using the validated Charlson comorbidity index and ASA performance status (ASA). Preoperative inflammation was quantified using clinically relevant values derived from haemoglobin concentration, serum albumin, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and modified Glasgow Prognostic Score (mGPS). Influence of each factor on overall survival (OS), disease free survival (DFS) and local recurrence free survival (LRFS) were assessed using Cox regression analysis. RESULTS: 388 of 506 resections met the inclusion criteria over this period. 256 PE for LARC and 132 PE for LRRC. Only mGPS ≥1 and ASA III were significant on multivariate analysis as negative prognostic markers for OS, DFS and LRFS in patients with LARC with Hazard ratios ranging from 1.94 to 3.82. For patients with LRRC ASA III was associated with reduced OS (p = 0.005) and LRFS (p = 0.039). CONCLUSIONS: Despite broadly similar baseline clinical characteristics for LARC and LRRC there are significant differences in the effect of these factors upon long term outcomes. Key clinical factors that influence survival are readily identifiable and easy to measure preoperatively. These factors may help stratify and quantify the risk of recurrence in LARC; however, further prognostic clinical markers for LRRC remain to be fully elucidated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pelvic ExenterationRectal NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMaleRetrospective StudiesMiddle AgedAgedSurvival RateDisease-Free SurvivalPrognosisAdultNeoadjuvant TherapyAged, 80 and overSerum AlbuminNeoplasm StagingComorbidity

Stichwörter der Autor:innen

Locally advancedOutcomePelvic exenterationRectal cancerRecurrentSurvival

Substanzen

Serum Albumin

Autor:innen und Institutionen

  • Complex Cancer Clinic, St Mark's- The National Bowel Hospital, Harrow, UK; School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
  • Complex Cancer Clinic, St Mark's- The National Bowel Hospital, Harrow, UK; Department of Surgery and Cancer, Imperial College, London, UK.
  • School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK; Department of Surgery, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
  • Complex Cancer Clinic, St Mark's- The National Bowel Hospital, Harrow, UK; School of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK; Department of Surgery and Cancer,…

Zitieren

APA

Gould, L. E., Pring, E. T., Wallace, A., Hodges, N., Burns, E. M., Steele, C. W., Roxburgh, C. S., & Jenkins, J. T. (2025). Clinical determinants of outcome following pelvic exenteration for locally advanced or locally recurrent rectal cancer. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110347

Vancouver

Gould LE, Pring ET, Wallace A, Hodges N, Burns EM, Steele CW, et al. Clinical determinants of outcome following pelvic exenteration for locally advanced or locally recurrent rectal cancer. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110347

BibTeX
@article{Gould2025,
  author = {Gould, Laura E and Pring, E Toby and Wallace, Alison and Hodges, Nicola and Burns, Elaine M and Steele, Colin W and Roxburgh, Campbell Sd and Jenkins, John T},
  title = {Clinical determinants of outcome following pelvic exenteration for locally advanced or locally recurrent rectal cancer},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.110347}
}
Kostenlos starten →